Stage III non-small cell lung cancer (NSCLC)Combination chemoradiotherapy for NSCLCIn this review the following topics are discussed: the complexities of clinical staging in locally advanced non-small cell lung
The use of chemotherapy is considered standard therapy in patients with locally advanced non-small-cell lung cancer that cannot be treated with radiotherapy and in those with metastatic non-small-cell lung cancer and good performance status. This approach is also accepted in patients with earlier st...
Fucosterol, a sterol isolated from brown algae, has been demonstrated to have anti-cancer properties. However, the effects and underlying molecular mechanism of fucosterol on non-small cell lung cancer remain to be elucidated. In this study, th
SUMMARYOver the last fifteen years, significant advances have been made in understanding the mechanisms and pathways that drive tumor growth in patients with non-small cell lung cancer (NSCLC). Molecular testing has become routine, and results directly impact clinical decision-making. The discovery ...
Blumenschein GR., Jr Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC) . Invest New Drugs (2012) 30 ( 4 ):1802–1110.1007/s10637-011-9750-1 [ Cross Ref ]George R., Blumenschein. (2011) Developmental antiangiogenic agents for the treatment of Non...
Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C (2016) Novel immunotherapy in the treatment of advanced non- small cell lung cancer. Expert Rev Clin Pharmacol 9:1571-1581Novel immunotherapy in the treatment of advanced non-small cell lung cancer. Santabarbara G,Maione P,Rossi A...
There are many treatments for your non-small-cell lung cancer (NSCLC). Like any medical condition, it's an ongoing process. “When you hear you have lung cancer, it’s a challenging and shocking diagnosis,” says Roy Herbst, MD, Chief of Medical Oncology/Hematology at Yale Cancer Center ...
Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalized treatment p
Journal for ImmunoTherapy of Cancer (2018) 6:75 https://doi.org/10.1186/s40425-018-0382-2 POSITION ARTICLE AND GUIDELINES Open Access The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) Julie R. Brahmer1, ...
The efficacy of checkpoint inhibitor (CPI) immunotherapy in patients with non–small cell lung cancer (NSCLC) is limited by a lack of strongly predictive response markers, subjecting patients to potential underutilization of alternative effective treatments, increased risk for futile care, and unnecessar...